DOI-NDEPA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
DOI-NDEPA is a chemical compound of the phenethylamine, DOx, and NDEPA families.[1] It is the N-(N,N-diethylpropylamide) (NDEPA) derivative of the psychedelic drug DOI.[1] The drug can also be thought of as a derivative of DOI with an LSD-like N,N-diethylamide moiety.[1] A quantitative structure–activity relationship (QSAR) predicted that DOI-NDEPA would bind with high affinity to the serotonin 5-HT2A receptor.[1] Its predicted affinity (Ki) was 3.2 nM.[1] DOI-NDEPA was first described in the scientific literature by 1999.[1]
| |
| Clinical data | |
|---|---|
| Other names | NDEPA-DOI; "Compound ko3"[1] |
| Drug class | Possible serotonin 5-HT2A receptor modulator[1] |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C18H29IN2O3 |
| Molar mass | 448.345 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
